Nanjing Hicin Pharmaceutical Co Ltd (300584) - Total Assets
Based on the latest financial reports, Nanjing Hicin Pharmaceutical Co Ltd (300584) holds total assets worth CN¥1.53 Billion CNY (≈ $224.15 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Nanjing Hicin Pharmaceutical Co Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Nanjing Hicin Pharmaceutical Co Ltd - Total Assets Trend (2012–2025)
This chart illustrates how Nanjing Hicin Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See net assets of Nanjing Hicin Pharmaceutical Co Ltd for net asset value and shareholders' equity analysis.
Nanjing Hicin Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Nanjing Hicin Pharmaceutical Co Ltd's total assets of CN¥1.53 Billion consist of 25.1% current assets and 74.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 4.3% |
| Accounts Receivable | CN¥190.44 Million | 12.4% |
| Inventory | CN¥76.58 Million | 5.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥121.74 Million | 8.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Nanjing Hicin Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Nanjing Hicin Pharmaceutical Co Ltd (300584) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanjing Hicin Pharmaceutical Co Ltd's current assets represent 25.1% of total assets in 2025, a decrease from 42.9% in 2012.
- Cash Position: Cash and equivalents constituted 4.3% of total assets in 2025, down from 15.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 6.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 12.4% of total assets.
Nanjing Hicin Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Nanjing Hicin Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.03 Billion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $36.83 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Humanwell Healthcare Group Co Ltd
SHG:600079
|
China | CN¥37.56 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Nanjing Hicin Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.07 | 1.01 | 1.24 |
| Quick Ratio | 0.83 | 0.75 | 0.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥23.95 Million | CN¥3.90 Million | CN¥51.58 Million |
Nanjing Hicin Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Nanjing Hicin Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.53 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | 4.6% |
| Total Assets | CN¥1.53 Billion |
| Market Capitalization | $650.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values Nanjing Hicin Pharmaceutical Co Ltd's assets below their book value (0.42x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Nanjing Hicin Pharmaceutical Co Ltd's assets grew by 4.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Nanjing Hicin Pharmaceutical Co Ltd (2012–2025)
The table below shows the annual total assets of Nanjing Hicin Pharmaceutical Co Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.53 Billion ≈ $224.19 Million |
+4.61% |
| 2024-12-31 | CN¥1.46 Billion ≈ $214.31 Million |
+3.95% |
| 2023-12-31 | CN¥1.41 Billion ≈ $206.16 Million |
+8.88% |
| 2022-12-31 | CN¥1.29 Billion ≈ $189.34 Million |
-0.62% |
| 2021-12-31 | CN¥1.30 Billion ≈ $190.52 Million |
+43.63% |
| 2020-12-31 | CN¥906.52 Million ≈ $132.65 Million |
+4.30% |
| 2019-12-31 | CN¥869.18 Million ≈ $127.19 Million |
+9.44% |
| 2018-12-31 | CN¥794.19 Million ≈ $116.21 Million |
+25.60% |
| 2017-12-31 | CN¥632.30 Million ≈ $92.53 Million |
+70.53% |
| 2016-12-31 | CN¥370.78 Million ≈ $54.26 Million |
+14.92% |
| 2015-12-31 | CN¥322.63 Million ≈ $47.21 Million |
+9.82% |
| 2014-12-31 | CN¥293.78 Million ≈ $42.99 Million |
+21.69% |
| 2013-12-31 | CN¥241.42 Million ≈ $35.33 Million |
+26.61% |
| 2012-12-31 | CN¥190.67 Million ≈ $27.90 Million |
-- |
About Nanjing Hicin Pharmaceutical Co Ltd
Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company's products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for … Read more